Tumor Biology

, Volume 36, Issue 8, pp 5801–5805 | Cite as

Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation

  • Ondrej Fiala
  • Milos Pesek
  • Jindrich Finek
  • Marek Minarik
  • Lucie Benesova
  • Zbynek Bortlicek
  • Ondrej Topolcan
Research Article


Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent novel effective agents approved for the treatment of patients with advanced-stage NSCLC. KRAS mutations have been reported as a negative prognostic and predictive factor in patients with NSCLC treated with EGFR-TKIs. Several studies have recently shown that statins can block tumour cell growth, invasion and metastatic potential. We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. Twelve patients were treated with combination of EGFR-TKI and statin and 55 patients were treated with EGFR-TKI alone. Comparison of patients’ survival (progression-free survival (PFS) and overall survival (OS)) according to the treatment used was performed using the Gehan-Wilcoxon test. The median of PFS and OS for patients treated with EGFR-TKI alone was 1.0 and 5.4 months compared to 2.0 and 14.0 months for patients treated with combination of EGFR-TKI and statin (p = 0.025, p = 0.130). In conclusion, the study results suggest significant improvement of PFS for patients treated with combination of statin and EGFR-TKI, and the difference in OS was not significant.


Statin KRAS Lung cancer NSCLC EGFR-TKI Erlotinib Gefitinib 



The authors would like to thank all patients voluntarily taking part in this study. This work was supported by the grant no. 9087 of the Czech Ministry of Health and by the project CZ.1.05/2.1.00/03.0076 from European Regional Development Fund.

Conflicts of interest



  1. 1.
    Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–43.CrossRefPubMedGoogle Scholar
  2. 2.
    Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18:1059–68.CrossRefPubMedGoogle Scholar
  3. 3.
    Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. J Thorac Oncol. 2006;1:7–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–65.CrossRefPubMedGoogle Scholar
  5. 5.
    Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol. 2010;17:1168–76.CrossRefPubMedGoogle Scholar
  6. 6.
    Lopez-Chavez A, Carter CA, Giaccone G. The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. Curr Opin Investig Drugs. 2009;10:1305–14.PubMedGoogle Scholar
  7. 7.
    Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069–75.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia. 2009;11:1084–92.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, et al. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res. 2010;30:5121–8.PubMedGoogle Scholar
  11. 11.
    Liu HP, Isaac Wu HD, Chang JW, Wu YC, Yang HY, Chen YT, et al. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. J Thorac Oncol. 2010;5:1175–84.CrossRefPubMedGoogle Scholar
  12. 12.
    Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet. 2013;206:26–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9(1):10–9.PubMedGoogle Scholar
  14. 14.
    Keyomarsi K, Sandoval L, Band V, et al. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 2003;9:10–9.Google Scholar
  15. 15.
    Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508–19.CrossRefPubMedGoogle Scholar
  16. 16.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefGoogle Scholar
  17. 17.
    Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Pruitt K, Der CJ. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 2001;171:1–10.CrossRefPubMedGoogle Scholar
  19. 19.
    Han JY, Lee SH, Yoo NJ, Hyung LS, Moon YJ, Yun T, et al. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2011;17:1553–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, et al. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells. Cell Death Dis. 2013;4:e814.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Park IH, Kim JY, Jung JI, Han JY. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs. 2010;28:791–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Fiala O, Pesek M, Finek J, Krejci J, Ricar J, Bortlicek Z, et al. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma. 2013;60:26–32.CrossRefPubMedGoogle Scholar
  23. 23.
    Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483–91.PubMedGoogle Scholar
  24. 24.
    Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol. 2001;13:491–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110–24.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ondrej Fiala
    • 1
    • 2
  • Milos Pesek
    • 3
  • Jindrich Finek
    • 1
  • Marek Minarik
    • 4
    • 5
  • Lucie Benesova
    • 4
  • Zbynek Bortlicek
    • 6
  • Ondrej Topolcan
    • 7
  1. 1.Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in PilsenCharles University in PraguePilsenCzech Republic
  2. 2.Biomedical Center, Faculty of Medicine in PilsenCharles University in PraguePragueCzech Republic
  3. 3.Department of Pneumology, Medical School and Teaching Hospital in PilsenCharles University in PraguePragueCzech Republic
  4. 4.Center for Applied Genomics of Solid TumoursGenomac Research InstitutePragueCzech Republic
  5. 5.Department of Analytical Chemistry, Faculty of SciencesCharles University in PraguePragueCzech Republic
  6. 6.Institute of Biostatistics and Analysis, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  7. 7.Department of Nuclear Medicine, Medical School and Teaching Hospital in PilsenCharles University in PraguePragueCzech Republic

Personalised recommendations